Conclusions
breast cancers
ADVERSE EFFECTS, BREAST CANCER
In this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy. Longer follow-up in this trial and forthcoming results of similar trials will provide additional insight into the potential HRQOL benefits of omitting breast surgery for highly selected patients whose breast cancers have a pCR to NST.